The NCRC AD case collection is one of the largest in the world, and has been used for identification of many genes involved in AD pathogenesis, including the filaggrin discovery.
Alan IrvineConsultant Dermatologist, Professor
Alan graduated in Medicine from Queen’s University Belfast (QUB) in 1991. In 1998, he was awarded a research doctorate (MD) in Human Genetics, also from QUB. He completed Dermatology Training in Belfast in July 1999, followed by fellowships in Great Ormond Street Children’s Hospital, and Children’s Memorial Hospital Chicago, where he was a Fulbright Scholar.
He was appointed Consultant Dermatologist (Attending Physician) in Children’s Health Ireland at Crumlin (CHI at Crumlin) and St. James’s Hospital, Dublin, Ireland in October 2002. The CHI at Crumlin department provides specialist clinics in severe atopic dermatitis, vascular malformations, laser treatments, and genetic skin diseases with more than 10 000 secondary and tertiary paediatric attendances per annum. His adult clinics provide a service for complex atopic dermatitis and genodermatoses.
He is Professor in Dermatology, Trinity College Dublin. His research interests are in epithelial genetics, disease mechanisms in, and therapy of, atopic dermatitis. His work on the genetics of atopic dermatitis with long term collaborative partner Irwin McLean has helped refocus attention on the role of the skin barrier in the pathogenesis of this disease and of allergic disease in general. He is funded by the National Children’s Research Centre and the Wellcome Trust, and has attracted approximately €11M funding to date.
Alan IrvineConsultant Dermatologist, Professor
The NCRC AD case collection is one of the largest in the world, and has been used for identification of many genes involved in AD pathogenesis, including the filaggrin discovery.
We have long standing research programs examining skin barrier function in atopic dermatitis. We use non-invasive techniques such as Raman spectroscopy and tape stripping to gain mechanistic and functional insights into AD pathogenesis.
We provide care for a large cohort of patients with vascular anomalies and overgrowth syndromes. We collaborate with investigators in Belgium on gene identification and with companies developing novel therapies.
For the last two decades we have worked on identification of causal genetic mutations in children with genetic skin disorders.
The list of publications below is automatically derived from MEDLINE/PubMed. As a result, there may be incorrect or missing publications.
| Name: | Professor Irwin McLean |
| Department | Human Genetics |
| Institution: | University of Dundee |
| Country: | UK |
| Name: | Dr Sanja Kezic |
| Department | Toxicology |
| Institution: | Academic Medicine Centre Amsterdam |
| Country: | Netherlands |
| Name: | Professor Stephan Weidinger |
| Department | Dermatology |
| Institution: | Kiel |
| Country: | Germany |
| Study Name | Study Title | Study Type | Sponsor | Sponsor Type |
|---|---|---|---|---|
| TREAT | A randomised clinical trial to assess the treatment safety and efficacy of oral methotrexate (MTX) vs ciclosporin (CyA) in the treatment of severe recalcitrant atopic eczema (AE) in children | Clinical Trial | King’s College London and Guy’s and St. Thomas’ NHS Foundation Trust | Academic - Investigator Led |
| EASE | Double-blind, Randomised, Vehicle-controlled, Phase III, Efficacy and Safety Study with 24-month Open-label Follow-up of Oleogel-S10 in Patients with Inherited Epidermolysis Bullosa | Clinical Trial | Amryt | Industry Sponsored |
| BADBIR | British Association of Dermatologists Biologic Interventions Register | Non-Interventional Study | University of Manchester | Academic - Collaborative Group |
| AD Real World | A Real World Evaluation to Describe Resource Use for the Management of Moderate to Severe Atopic Dermatitis in Secondary Care for Children and Adolescents Aged 6 to 17 in the Republic of Ireland | Non-Interventional Study | Sanofi | Industry Sponsored |
| VAD | Understanding T-Cell Immunity in Atopic Dermatitis Patients: Relevance to Staphylococcal Aureus Vaccine Design | Non-Interventional Study | ||
| MEASURE AD | Global Cross-Sectional Burden-of- Illness Study in Adolescent and Adult Patients with Atopic Dermatitis. | Non-Interventional Study | AbbVie | Industry Sponsored |
| EPIK-P1 | Retrospective Chart Review Study of Patients with PIK3CA- Related Overgrowth Spectrum (PROS) who have received alpelisib as part of a compassionate use program. | Non-Interventional Study | Novartis | Industry Sponsored |
| Study Name | Study Title | Study Type | Sponsor | Sponsor Type |
|---|---|---|---|---|
| Eczema & Food Allergy | Identification of Major Susceptibility Genes for Eczema and Food Allergy | Non-Interventional Clinical Trial | ||
| Whole Exome Sequencing | Whole exome screening and next generation sequencing | Non-Interventional Study | University of Dundee | Academic-Investigator Led |
| Regional Filaggrin | A Study to Investigate Regional Filaggrin Expression | Non-Interventional Study | ||
| DS107E-05 | A prospective, randomised, vehicle-controlled, double-blind, exploratory clinical trial to assess the efficacy and steroid sparing potential of DGLA cream topically applied to early childhood patients with moderate to severe atopic dermatitis | Clinical Trial | Afimmune | Industry Sponsored |
| Overgrowth genetics projects | Clinical and molecular characterization of PIK3Kinase related Overgrowth Syndromes | Non-Interventional Study | Cambridge University | Academic-Investigator Led |
| Vascular malformation projects | Clinical and molecular characterization of hyperkeratotic vascular malformations | Non-Interventional Study | Université Catholique de Louvain | Academic-Investigator Led |
| Inflazome CAPS | MCC950 and derivatives in CAPS patients | Non-Interventional Study | Inflazome Ltd / Trinity College Dublin | Academic - Investigator Led |
| PRiTI | Clinical, immunologic and microbiologic characterisation of early onset atopic eczema: A study to identify factors in disease initiation, severity, flare and resolution. | Non-Interventional Study | ||
| APPLES | A prospective paediatric study to assess the long-term safety of tacrolimus ointment for the treatment of atopic dermatitis. | Non-Interventional Clinical Trial | Astellas Pharma | Industry Sponsored |
| ARQ-092 | A Phase 1/2 Study of ARQ 092 in Patients With Overgrowth Diseases and Vascular Anomalies With Genetic Alterations of the PI3K/AKT Pathway | Clinical Trial | Arqule | Industry Sponsored |
Alan is a former Section Editor of the Journal of Investigative Dermatology and an Associate Editor of Allergy, and was the Lead Editor of the 3rd Edition of Harper’s Textbook of Pediatric Dermatology (2011). He is an Honorary Professor in the School of Life Sciences, University of Dundee. In 2016 he was awarded a DSc from Queens University Belfast in recognition of his skin barrier research.
Alan’s international awards include: 2006/2007 Paul Gerson Unna Prize from the German Dermatology Society, 2013 Jerry Dolovich Memorial Lecture (AAAAI), 2015 Dr Sydney Watson Smith Lecture (Royal College of Physicians of Edinburgh), 2016 RW Goltz Memorial Lecture (University of Minnesota).
Other positions and responsibilities: